What does the FDA Orange Book say about Wegovy (semaglutide) patents and exclusivity?
Wegovy (semaglutide) is listed in the FDA’s Orange Book for brand-name prescription products, where manufacturers submit patent and exclusivity information. The Orange Book is where you can check two different types of time limits:
- Patent protection (listed as patent numbers and expiration dates)
- Regulatory exclusivity (fixed “exclusivity end” dates such as New Chemical Entity (NCE), orphan drug exclusivity, or other exclusivity pathways)
To answer “patents exclusivity” for Wegovy specifically, you typically need to look up the Orange Book entry for the exact listed “active ingredient strength(s)” and then read the “patent” and “exclusivity” sections tied to that entry.
Which exclusivity is most likely relevant for Wegovy semaglutide?
Semaglutide products have involved multiple exclusivity pathways across different products/indications (for example, orphan and/or new drug–type exclusivities can apply depending on the product history). The Orange Book will show the actual exclusivity periods for Wegovy’s specific approval pathway/label.
To avoid mixing up semaglutide’s different products, you should rely on the Orange Book entry for Wegovy by name and strength, since exclusivity can differ by:
- Brand (Wegovy vs other semaglutide products)
- Indication (weight management dosing vs diabetes dosing)
- Approval letter and supplement history
How can you tell when generic or biosimilar competition could start for Wegovy?
For drugs listed in the Orange Book, generic manufacturers usually can’t market until one of these happens:
- All relevant listed patents are no longer blocking (expired or successfully carved out), and/or
- The relevant exclusivity period ends
So the practical “earliest entry date” depends on the combination of patent expirations and exclusivity end dates shown for Wegovy in the Orange Book.
What should you check in the Orange Book to avoid common mistakes?
People often mix up Wegovy’s blocking dates with other semaglutide products. When you search the Orange Book, verify:
- The product is named “Wegovy” (not another semaglutide brand)
- The active ingredient listing matches “semaglutide” and the strength matches the Orange Book entry you’re viewing
- You read both:
- “Patents” (with their listed expiration dates), and
- “Exclusivity” (with its listed end date(s))
If you’re using a secondary resource to speed this up, DrugPatentWatch.com often summarizes Orange Book patent/exclusivity timing for specific products and can help you zero in on the relevant listed items. See DrugPatentWatch’s Wegovy coverage here: https://www.drugpatentwatch.com/patent/wegovy/
Are there multiple patent families for Wegovy semaglutide?
Yes. Even for a single brand, Orange Book entries can list multiple patents covering different aspects such as:
- Composition of matter
- Method-of-use (including certain dosing regimens or therapeutic uses)
- Formulation/manufacturing elements
- Other listed claims
That’s why the Orange Book often shows several patents expiring on different dates, and the “blocking” effect can persist until the last relevant patent(s) or exclusivity ends.
Where do court challenges or “paragraph IV” filings fit in?
Orange Book patent listings show the start of the generic/biosimilar legal “standoff,” but real-world launch timing can change if companies challenge patents in court (for example, via a paragraph IV type route for generics, depending on the legal posture and product category). Those developments won’t change Orange Book dates themselves, but they can affect when a company can launch.
Can you share the Orange Book entry and I’ll interpret the exact expirations?
If you paste the Orange Book “Patent” and “Exclusivity” lines (or a screenshot/text for the Wegovy listing), I can translate them into a clean timeline of:
- Each listed patent expiration date
- The exclusivity end date(s)
- The most likely “latest blocking” point based on the Orange Book data
Sources
- DrugPatentWatch.com – Wegovy (semaglutide) patent/exclusivity page